戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 of the 21 subjects who received stings had a systemic reaction.
2 lergens (PR-10 and profilin) sometimes cause systemic reaction.
3  in spite of injection pain and high risk of systemic reaction.
4 ch a diagnosis and may predict the risk of a systemic reaction.
5 stration is associated with a risk of severe systemic reactions.
6 of SD-QIV, with comparable injection-site or systemic reactions.
7 ad similar frequencies of injection site and systemic reactions.
8 tization was strongly associated with severe systemic reactions.
9 n of metabolic regulation in aspirin-induced systemic reactions.
10 ed challenge carries a high risk of inducing systemic reactions.
11 rious adverse events and solicited local and systemic reactions.
12 al or rhinoconjunctival symptoms, and 49 had systemic reactions.
13 ed a second large local reaction and 24% had systemic reactions.
14 e-stings and assessed for risk of subsequent systemic reactions.
15 anut-allergic subjects suffering from severe systemic reactions.
16  exercise, were other relevant cofactors for systemic reactions.
17 rointestinal AEs, and AR predicted increased systemic reactions.
18               There were no serious local or systemic reactions.
19  reported a higher incidence of food-induced systemic reactions.
20 ated with mostly mild and transient local or systemic reactions.
21   Ultrarush initiation increases the risk of systemic reactions.
22 dministration intervals, but it caused fewer systemic reactions.
23 es include nuisance biting and cutaneous and systemic reactions.
24  safety outcomes were frequency of local and systemic reactions.
25 een reported, including cutaneous and rarely systemic reactions.
26 that are associated with a high incidence of systemic reactions.
27 atients (8.3% of all patients) experienced 6 systemic reactions (0.15% of doses).
28           Anaphylactic shock (76.6%), severe systemic reactions (10.5%), acute laryngeal edema (9%),
29 form of meat allergy characterized by severe systemic reactions 3-7 h after consumption of red meat.
30 ll tolerated, with occasional, usually mild, systemic reactions (abdominal pain, arthralgia, and diar
31          However, rates of local induration, systemic reactions, adverse events (AEs), and SAEs were
32            Currently, the risk of subsequent systemic reactions after re-stings is considered low (2%
33                                    Local and systemic reactions after vaccination with LC16m8 were si
34                                              Systemic reactions, after a previous large local reactio
35  primary outcome was safety (e.g., local and systemic reactions and adverse events); immunogenicity w
36 blet (SLIT-tablet) treatment, such as severe systemic reactions and asthma-related events.
37                        Local and unsolicited systemic reactions and humoral responses were also asses
38                                     However, systemic reactions and intolerable gastrointestinal AEs
39 ll-tolerated with only grade 1 to 2 local or systemic reactions and no treatment-limiting adverse eve
40 mong children with FA, the history of severe systemic reactions and the presence of multiple FAs were
41    Approximately 42% of subjects experienced systemic reactions, and 49% experienced gastrointestinal
42 se showed promising efficacy, small risk for systemic reactions, and immunomodulatory changes in this
43 avenous immunoglobulin (IGIV), induces fewer systemic reactions, and may be self-infused.
44   Vaccine administration induced no local or systemic reactions, and no laboratory abnormalities were
45 -1.4; P = .01) but less likely to report any systemic reaction (aOR, 0.7; 95% CI, 0.6-0.8; P < .001).
46                  PR-10- and profilin-induced systemic reactions are facilitated by PPI, ingestion of
47                                              Systemic reactions are further categorized within each g
48              A 51-year-old woman experienced systemic reactions beginning 10 days after cadaveric ren
49  with no significant differences in local or systemic reactions between groups.
50                          Solicited local and systemic reactions between treatment and placebo group w
51 se 4 was associated with increased local and systemic reactions, but the overall safety profile of a
52  all patients suggesting a radiation-induced systemic reaction; (c) changes in DTPA t 1/2 values were
53 (pain, erythema, induration, and warmth) and systemic reactions (chills, arthralgias, and myalgias) i
54  Sixty-four percent of vaccinees experienced systemic reactions, compared with 53% of placebo recipie
55 ted with significant increases in reports of systemic reactions during days 0 to 7 following vaccinat
56 me was the occurrence of 1 or more objective systemic reactions during venom immunotherapy initiation
57                     Local injection site and systemic reactions (eg, fatigue, headache, and myalgia)
58    Participants reported solicited local and systemic reactions for 7 days following vaccination and
59          Treatment options for cutaneous and systemic reactions from bed bug bites have not been eval
60 p large local swelling or strictly cutaneous systemic reactions generally do not require immunotherap
61  frequently reported adverse events included systemic reactions (Group 1: 21% of patients, Group 2: 3
62 ed and who had a history of mild (cutaneous) systemic reaction (i.e., one with only cutaneous manifes
63 .14) were slightly more likely to report any systemic reaction in the week following simultaneous vac
64 ) of 49 in the 70 years and older group, and systemic reactions in 42 (86%) participants in the 18-55
65   We sought to investigate the occurrence of systemic reactions in children with isolated sensitizati
66 s one or more participant-reported solicited systemic reactions in the 7 days after first trial vacci
67 er incidence of mild, self-limited local and systemic reactions in the vaccine group, but only during
68 well tolerated, with no significant local or systemic reactions in the women and no adverse outcomes
69 om immunotherapy may reduce the incidence of systemic reactions in those with a history of venom-trig
70                                              Systemic reactions included mild to moderate malaise and
71  after D2 (85% D1 versus 78% D2, P < 0.001), systemic reactions increased (49% D1 versus 69% D2, P <
72 nd in untreated patients with a history of a systemic reaction involving at least two different organ
73                                         This systemic reaction is caused by the rapid release of a la
74 as associated with mild-to-moderate local or systemic reactions lasting a median of three days.
75                       Local, mild, or severe systemic reactions may occur already after the first con
76               Aside from transient local and systemic reactions, no safety concerns were identified.
77 s (aP) vaccines has considerably reduced the systemic reactions observed with diphtheria-tetanus toxo
78 en (19%) patients were taking a PPI when the systemic reaction occurred (vs 5% in controls; P < .025)
79                               In total, four systemic reactions occurred (two grade I and two grade I
80                                              Systemic reactions occurred less frequently in patients
81                                              Systemic reactions occurred without any identifiable cof
82                                     Local or systemic reactions occurred, respectively, in 40 (78%) a
83                                           No systemic reactions occurred.
84                                    Local and systemic reactions occurring during the first 7 days aft
85  The acute-phase response (APR) represents a systemic reaction of the organism to multiple nonspecifi
86  70%-90% of clinical trial participants, and systemic reactions of fever and fatigue were reported in
87 eater number of moderate or severe local and systemic reactions (of 16 participants, 4 had local reac
88   There was no pattern of vaccine-associated systemic reactions or clinically significant laboratory
89 1.0 kUA /l conferred a 97% probability for a systemic reaction (P = 0.0002).
90 sociated with a higher frequency of local or systemic reactions (P = 0.001, both).
91 ensitization and region on the occurrence of systemic reactions (P = 0.0185 and P = 0.0436, respectiv
92 nts of the higher dose had greater local and systemic reactions (P<.001).
93 , 7 had local reactions [P < 0.01] and 0 had systemic reactions [P < 0.001]).
94 ntrast administration can be associated with systemic reactions, renal disease, and thyroid dysfuncti
95                                            A systemic reaction (SR) occurred in 28 out of 33 (84.8%)
96 e two groups; the safety was assessed by the systemic reaction (SR) rate.
97 he association between sBT levels and severe systemic reactions (SR).
98             Outside clinical trials, data on systemic reactions (SRs) due to allergen immunotherapy (
99                                     To avoid systemic reactions, stepwise SPT is mandatory.
100 iated with a lower incidence and severity of systemic reactions than BNT162b1, particularly in older
101  fact stimulate more robust inflammatory and systemic reactions than RF at liver ablation, the author
102 rticipants, 4 had local reactions and 13 had systemic reactions) than did vaccine formulated with MF5
103 errulatus-envenomed victims exhibit local or systemic reaction that culminates in pulmonary oedema, p
104                              Trauma evokes a systemic reaction that includes an acute, non-specific,
105                    Four subjects had adverse systemic reactions that may have resulted from the inten
106 against GVHD, vaccination elicited local and systemic reactions that were qualitatively similar to th
107 f-reported questionnaire regarding local and systemic reactions through a dedicated mobile applicatio
108   There is evidence that the severity of the systemic reaction to infection (severe sepsis) is strong
109  is a rapidly progressing, life-threatening, systemic reaction to invasive infection caused by group
110 d food challenge, 1 boy with a previous mild systemic reaction to peanut experienced lip swelling, st
111 ldren leads to a significantly lower risk of systemic reaction to stings even 10 to 20 years after tr
112 riencing any symptoms, whereas others suffer systemic reactions to 10 mg or less.
113 espiratory symptoms but inversely related to systemic reactions to food.
114 sp venom, and 32 controls without history of systemic reactions to Hymenoptera stings and no sIgE to
115  known to occur in a subset of patients with systemic reactions to Hymenoptera stings.
116 re considered to be a risk factor for severe systemic reactions to hymenoptera stings.
117 tosis and/or elevated sBT tryptase level and systemic reactions to hymenoptera venoms were analyzed f
118 ificantly associated with the development of systemic reactions to peanut.
119                                 No severe or systemic reactions to vaccination occurred, and five ser
120                                         Most systemic reactions to vaccination were mild or moderate.
121 int was the frequency of solicited local and systemic reactions to vaccination.
122     If the child had a documented history of systemic reactions up to grade I anaphylaxis, double-bli
123 plasma tryptase and EDN, and the severity of systemic reactions was correlated with levels of tryptas
124                       The risk of subsequent systemic reactions was higher in case of skin test react
125 predictive role of large local reactions for systemic reactions, we demonstrated that an accurate dia
126 traoral, throat and facial swellings, but no systemic reaction were observed.
127                           Injection-site and systemic reactions were assessed for 7 days post-vaccina
128                                              Systemic reactions were counted to evaluate safety.
129 ccine immunogenicity, and rates of local and systemic reactions were determined.
130                                    Local and systemic reactions were generally mild and, except for p
131                          Solicited local and systemic reactions were generally mild or moderate in bo
132                                    Local and systemic reactions were generally mild to moderate in th
133                              The most common systemic reactions were headache, malaise, and myalgia.
134                             Soy milk-induced systemic reactions were independent of PPI treatment.
135                                              Systemic reactions were less frequent with IGHy than wit
136 hough the overall reaction rate was similar, systemic reactions were more common during OIT than duri
137                                    Local and systemic reactions were more common in participants give
138                                    Local and systemic reactions were more common in participants give
139                                    Local and systemic reactions were more common in the ChAdOx1 nCoV-
140                                    Local and systemic reactions were more frequent after dose 4.
141                                    Objective systemic reactions were more likely during ultrarush ini
142               Although no acute cutaneous or systemic reactions were noted, endothelial cell activati
143                               Mild local and systemic reactions were noted.
144                                              Systemic reactions were rare, but local reactions (prima
145                      At the same age, severe systemic reactions were reported among 14 (19%) of 74 in
146       In the week following vaccination, any systemic reactions were reported by 36 144 (58.9%) of 61
147         Immunotherapy was well tolerated; no systemic reactions were reported.
148                                    Local and systemic reactions were similar between doses and strain
149 [aOR] = 4.53; 95% CI: [0.71, 28.9]), whereas systemic reactions were similar between groups with both
150               Rates of local and unsolicited systemic reactions were similar between the randomly ass
151                       Stage 3 is the massive systemic reaction where cytokines turn destructive by co
152 frequency and severity of injection-site and systemic reactions within 28 days of each vaccination.
153  The primary safety endpoints were local and systemic reactions within 7 days after each injection, a
154      Solicited reports of injection-site and systemic reactions within 7 days after vaccination were
155 , at 4-7 days for postimmunization local and systemic reactions, within 28 days for adverse events, a

 
Page Top